Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 LIMITATIONS
1.4 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MIDDLE EAST AND AFRICA STROKE MARKET, REGULATORY FRAMEWORK
5.1 REGULATION IN U.S.
5.2 REGULATION IN EUROPE
5.3 REGULATION IN CHINA
5.4 REGULATION IN JAPAN
5.5 REGULATION IN SOUTH AFRICA
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS
6.1.2 INCREASING NUMBER OF PATIENTS WITH HYPERTENSION AND CORONARY HEART DISEASES
6.1.3 INCREASING DIABETIC AND OBESE POPULATIONS ELEVATE STROKE RISKS
6.1.4 ADVANCEMENTS IN MEDICAL TECHNOLOGY IMPROVE STROKE CARE OUTCO.MES
6.2 RESTRAINTS
6.2.1 HIGH COST OF DIAGNOSIS
6.2.2 INCREASE IN PRODUCT RECALL
6.3 OPPORTUNITIES
6.3.1 DEVELOPMENT OF ADVANCED THERAPEUTICS FOR STROKES
6.3.2 EXPANSION IN STROKE REHABILITATION SERVICES
6.3.3 INNOVATIVE TREATMENTS IN PIPELINE FOR STROKE TREATMENT
6.4 CHALLENGES
6.4.1 FALSE DIAGNOSIS IN STROKES
6.4.2 COMPLICATIONS ASSOCIATED WITH MANAGING STROKE
7 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE
7.1 OVERVIEW
7.2 ISCHEMIC STROKE
7.2.1 THROMBOTIC (CEREBRAL THROMBOSIS)
7.2.2 EMBOLIC (CEREBRAL EMBOLISM)
7.3 HEMORRHAGIC STROKE
7.3.1 SUBARACHNOID HEMORRHAGE
7.3.2 INTRACEREBRAL HEMORRHAGE
7.4 TRANSIENT ISCHEMIC ATTACT (TIA)
8 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER
8.1 OVERVIEW
8.2 FEMALE
8.3 MALE
9 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT
9.1 OVERVIEW
9.2 TREATMENT
9.2.1 BY TREATMENT TYPE
9.2.1.1 MEDICATION
9.2.1.1.1 MEDICATION, BY CLASS
9.2.1.1.1.1 BLOOD PRESSURE MEDICINES
9.2.1.1.1.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
9.2.1.1.1.1.2 RAMIPRIL
9.2.1.1.1.1.3 LISINOPRIL
9.2.1.1.1.1.4 ENALAPRIL
9.2.1.1.1.1.5 PERINDOPRIL
9.2.1.1.1.1.6 OTHER
9.2.1.1.1.2 THIAZIDE DIURETICS
9.2.1.1.1.2.1 INDAPAMIDE
9.2.1.1.1.2.2 BENDROFLUMETHIAZIDE
9.2.1.1.1.2.3 SPIRONOLACTONE
9.2.1.1.1.2.4 AMILORIDE
9.2.1.1.1.2.5 OTHER
9.2.1.1.1.3 CALCIUM CHANNEL BLOCKERS
9.2.1.1.1.3.1 AMLODIPINE
9.2.1.1.1.3.2 NIFEDIPINE
9.2.1.1.1.3.3 VERAPAMIL
9.2.1.1.1.3.4 NICARDIPINE
9.2.1.1.1.3.5 FELODIPINE
9.2.1.1.1.3.6 NIMODIPINE
9.2.1.1.1.3.7 OTHERS
9.2.1.1.1.4 BETA BLOCKERS
9.2.1.1.1.4.1 ATENOLOL
9.2.1.1.1.4.2 BISOPROLOL
9.2.1.1.1.4.3 LABETOLOL
9.2.1.1.1.4.4 OTHERS
9.2.1.1.1.5 ALPHA-BLOCKERS
9.2.1.1.1.5.1 DOXAZOSIN
9.2.1.1.1.5.2 OTHERS
9.2.1.1.1.6 OTHERS
9.2.1.1.1.7 ANTIPLATELET DRUGS
9.2.1.1.1.7.1 ASPIRIN
9.2.1.1.1.7.2 CLOPIDOGREL
9.2.1.1.1.7.3 DIPYRIDAMOLE
9.2.1.1.1.7.4 TICLOPIDINE
9.2.1.1.1.7.5 OTHERS
9.2.1.1.1.8 ANTICOAGULANTS
9.2.1.1.1.8.1 WARFARIN
9.2.1.1.1.8.2 APIXABAN
9.2.1.1.1.8.3 DABIGATRAN
9.2.1.1.1.8.4 HEPARIN
9.2.1.1.1.8.5 RIVAROXABAN
9.2.1.1.1.8.6 OTHERS
9.2.1.1.1.9 TISSUE PLASMINOGEN ACTIVATOR (TPA)
9.2.1.1.1.9.1 ALTEPLASE
9.2.1.1.1.9.2 TENECTEPLASE
9.2.1.1.1.9.3 RETEPLASE
9.2.1.1.1.9.4 ANISTREPLASE
9.2.1.1.1.9.5 OTHERS
9.2.1.1.1.10 STATINS
9.2.1.1.1.10.1.1 ATORVASTATIN
9.2.1.1.1.10.1.2 SIMVASTATIN
9.2.1.1.1.10.1.3 LOVASTATIN
9.2.1.1.1.10.1.4 ROSUVASTATIN
9.2.1.1.1.10.1.5 FLUVASTATIN
9.2.1.1.1.10.1.6 PRAVASTATIN
9.2.1.1.1.10.1.7 PITAVASTATIN
9.2.1.1.1.10.1.8 OTHERS
9.2.1.1.1.11 VITAMIN K
9.2.1.1.1.12 SUPPORTIVE MEDICATION
9.2.1.1.1.12.1 NUTRITIONAL SUPPLEMENTS
9.2.1.1.1.12.2 ANTIPYRETICS
9.2.1.1.1.12.3 OTHERS
9.2.1.1.2 MEDICATION, BY DRUG TYPE
9.2.1.1.2.1 BRANDED
9.2.1.1.2.1.1 ACTIVASE
9.2.1.1.2.1.2 EDOBAXAN
9.2.1.1.2.1.3 COUMADIN
9.2.1.1.2.1.4 HEPARIN LEO
9.2.1.1.2.1.5 DUOPLAVIN
9.2.1.1.2.1.6 AGGRENOX
9.2.1.1.2.1.7 RETAVASE
9.2.1.1.2.1.8 JANTOVEN
9.2.1.1.2.1.9 CATHFLO
9.2.1.1.2.1.10 OTHER
9.2.1.1.2.2 GENERIC
9.2.1.1.3 MEDICATION, BY ROUTE OF ADMINISTRATION
9.2.1.1.3.1 ORAL
9.2.1.1.3.1.1 TABLET
9.2.1.1.3.1.2 CAPSULES
9.2.1.1.3.1.3 OTHERS
9.2.1.1.3.2 PARENTERAL
9.2.1.1.3.2.1 INTRAVENOUS
9.2.1.1.3.2.2 SUBCUTANEOUS
9.2.1.1.3.3 OTHERS
9.2.1.1.4 MEDICATION, BY MODE OF PURCHASE
9.2.1.1.4.1 PRESCRIPTION
9.2.1.1.4.2 OVER THE COUNTER (OTC)
9.2.1.1.5 MEDICATION, BY THERAPY TYPE
9.2.1.1.5.1 COMBINATION THERAPY
9.2.1.1.5.2 MONOTHERAPY
9.2.1.2 SURGERY
9.2.1.2.1 EMBOLIC COILS
9.2.1.2.2 ASPIRATION CATHETERS
9.2.1.2.3 STENT RETRIEVER
9.2.1.2.4 SURGICAL CLIPPING
9.2.1.2.5 OTHERS
9.2.1.3 OTHERS THERAPY
9.2.1.3.1 PHYSICAL THERAPY
9.2.1.3.2 OCCUPATIONAL THERAPY
9.2.1.3.3 SPEECH THERAPY
9.2.1.3.4 OTHERS
9.3 DIAGNOSIS
9.3.1 IMAGING TEST
9.3.1.1 COMPUTERIZED TOMOGRAPHY (CT) SCAN
9.3.1.2 MAGNETIC RESONANCE IMAGING (MRI)
9.3.1.3 CAROTID ULTRASOUND
9.3.1.4 CEREBRAL ANGIOGRAM
9.3.2 BLOOD TEST
9.3.3 ECHOCARDIOGRAM
9.3.4 LUMBAR PUNCTURE
9.3.5 OTHERS
10 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT
10.3 RETAIL
10.4 ONLINE
11 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER
11.1 OVERVIEW
11.2 HOSPITALS & CLINICS
11.3 SPECIALTY CLINICS
11.4 AMBULATORY SURGICAL CENTER
11.5 HOMECARE
11.6 LABORATORIES
11.7 OTHERS
12 MIDDLE EAST AND AFRICA STROKE MARKET, BY REGION
12.1 MIDDLE EAST AND AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 EGYPT
12.1.4 U.A.E.
12.1.5 ISRAEL
12.1.6 KUWAIT
13 MIDDLE EAST AND AFRICA STROKE MARKET, COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILES
15.1 BRISTOL-MYERS SQUIBB COMPANY
15.1.1 COMPANY SNAPSHOT
15.1.2 REVENUE ANALYSIS
15.1.3 COMPANY SHARE ANALYSIS
15.1.4 PRODUCT PORTFOLIO
15.2 F. HOFFMANN-LA ROCHE LTD
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENT
15.4 DAIICHI SANKYO COMPANY, LIMITED
15.4.1 COMPANY SNAPSHOT
15.4.2 REVENUE ANALYSIS
15.4.3 COMPANY SHARE ANALYSIS
15.4.4 PRODUCT PORTFOLIO
15.4.5 RECENT DEVELOPMENT
15.5 SANOFI
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.6 ABBOTT
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENT
15.7 AMNEAL PHARMACEUTICALS LLC
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENT
15.8 ASTRAZENECA
15.8.1 COMPANY SNAPSHOT
15.8.2 REVENUE ANALYSIS
15.8.3 PRODUCT PORTFOLIO
15.8.4 RECENT DEVELOPMENT
15.9 BAYER AG
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENT
15.1 FRESENIUS SE & CO. KGAA
15.10.1 COMPANY SNAPSHOT
15.10.2 REVENUE ANALYSIS
15.10.3 PRODUCT PORTFOLIO
15.10.4 RECENT DEVELOPMENT
15.11 GLENMARK PHARMACEUTICALS LTD.
15.11.1 COMPANY SNAPSHOT
15.11.2 REVENUE ANALYSIS
15.11.3 PRODUCT PORTFOLIO
15.11.4 RECENT DEVELOPMENT
15.12 JOHNSON & JOHNSON SERVICES, INC.
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENT
15.13 LUPIN
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.14 MEDTRONIC
15.14.1 COMPANY SNAPSHOT
15.14.2 REVENUE ANALYSIS
15.14.3 PRODUCT PORTFOLIO
15.14.4 RECENT DEVELOPMENT
15.15 PENUMBRA, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.16 PFIZER INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 REVENUE ANALYSIS
15.16.3 PRODUCT PORTFOLIO
15.16.4 RECENT DEVELOPMENT
15.17 SANDOZ AG
15.17.1 COMPANY SNAPSHOT
15.17.2 REVENUE ANALYSIS
15.17.3 PRODUCT PORTFOLIO
15.17.4 RECENT DEVELOPMENT
15.18 TEVA PHARMACEUTICALS USA, INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 REVENUE ANALYSIS
15.18.3 PRODUCT PORTFOLIO
15.18.4 RECENT DEVELOPMENT
15.19 VIATRIS INC.
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
16 QUESTIONNAIRE
17 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 5 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 6 MIDDLE EAST AND AFRICA TRANSIENT ISCHEMIC ATTACT (TIA) IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA FEMALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA MALE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINES IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 26 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 30 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 31 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 32 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 33 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 34 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 35 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 36 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 37 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 38 MIDDLE EAST AND AFRICA DIRECT IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 41 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 MIDDLE EAST AND AFRICA HOSPITALS & CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 43 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 44 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 45 MIDDLE EAST AND AFRICA HOMECARE IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 46 MIDDLE EAST AND AFRICA LABORATORIES IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 47 MIDDLE EAST AND AFRICA OTHERS IN STROKE MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 48 MIDDLE EAST AND AFRICA STROKE MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 49 MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 50 MIDDLE EAST AND AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 51 MIDDLE EAST AND AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 52 MIDDLE EAST AND AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 53 MIDDLE EAST AND AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 54 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 55 MIDDLE EAST AND AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 56 MIDDLE EAST AND AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 57 MIDDLE EAST AND AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 58 MIDDLE EAST AND AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 59 MIDDLE EAST AND AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 60 MIDDLE EAST AND AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 61 MIDDLE EAST AND AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 62 MIDDLE EAST AND AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 63 MIDDLE EAST AND AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 64 MIDDLE EAST AND AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 65 MIDDLE EAST AND AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 66 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 67 MIDDLE EAST AND AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 68 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 69 MIDDLE EAST AND AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 70 MIDDLE EAST AND AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 71 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 72 MIDDLE EAST AND AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 73 MIDDLE EAST AND AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 74 MIDDLE EAST AND AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 75 MIDDLE EAST AND AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 76 MIDDLE EAST AND AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 77 MIDDLE EAST AND AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 78 MIDDLE EAST AND AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 MIDDLE EAST AND AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 SOUTH AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 81 SOUTH AFRICA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 82 SOUTH AFRICA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 83 SOUTH AFRICA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 84 SOUTH AFRICA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 85 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 86 SOUTH AFRICA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 87 SOUTH AFRICA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 88 SOUTH AFRICA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 89 SOUTH AFRICA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 90 SOUTH AFRICA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 91 SOUTH AFRICA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 92 SOUTH AFRICA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 93 SOUTH AFRICA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 94 SOUTH AFRICA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 95 SOUTH AFRICA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 96 SOUTH AFRICA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 97 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 98 SOUTH AFRICA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 99 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 100 SOUTH AFRICA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 101 SOUTH AFRICA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 102 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 103 SOUTH AFRICA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 104 SOUTH AFRICA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 105 SOUTH AFRICA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 106 SOUTH AFRICA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 107 SOUTH AFRICA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 108 SOUTH AFRICA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 109 SOUTH AFRICA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 110 SOUTH AFRICA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 111 SAUDI ARABIA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 112 SAUDI ARABIA ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 113 SAUDI ARABIA HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 114 SAUDI ARABIA STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 115 SAUDI ARABIA TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 116 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 117 SAUDI ARABIA BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 118 SAUDI ARABIA ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 119 SAUDI ARABIA THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 120 SAUDI ARABIA CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 121 SAUDI ARABIA BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 122 SAUDI ARABIA ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 123 SAUDI ARABIA ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 124 SAUDI ARABIA ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 125 SAUDI ARABIA TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 126 SAUDI ARABIA STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 127 SAUDI ARABIA SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 128 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 129 SAUDI ARABIA BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 130 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 131 SAUDI ARABIA ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 132 SAUDI ARABIA PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 133 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 134 SAUDI ARABIA MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 135 SAUDI ARABIA SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 136 SAUDI ARABIA OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 137 SAUDI ARABIA DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 138 SAUDI ARABIA IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 139 SAUDI ARABIA STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 140 SAUDI ARABIA STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 141 SAUDI ARABIA STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 142 EGYPT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 143 EGYPT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 144 EGYPT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 145 EGYPT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 146 EGYPT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 147 EGYPT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 148 EGYPT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 149 EGYPT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 150 EGYPT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 151 EGYPT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 152 EGYPT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 153 EGYPT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 154 EGYPT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 155 EGYPT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 156 EGYPT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 157 EGYPT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 158 EGYPT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 159 EGYPT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 160 EGYPT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 161 EGYPT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 162 EGYPT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 163 EGYPT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 164 EGYPT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 165 EGYPT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 166 EGYPT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 167 EGYPT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 168 EGYPT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 169 EGYPT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 170 EGYPT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 171 EGYPT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 172 EGYPT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 173 U.A.E. STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 174 U.A.E. ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 175 U.A.E. HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 176 U.A.E. STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 177 U.A.E. TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 178 U.A.E. MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 179 U.A.E. BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 180 U.A.E. ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 181 U.A.E. THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 182 U.A.E. CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 183 U.A.E. BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 184 U.A.E. ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 185 U.A.E. ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 186 U.A.E. ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 187 U.A.E. TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 188 U.A.E. STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 189 U.A.E. SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 190 U.A.E. MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 191 U.A.E. BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 192 U.A.E. MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 193 U.A.E. ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 194 U.A.E. PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 195 U.A.E. MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 196 U.A.E. MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 197 U.A.E. SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 198 U.A.E. OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 199 U.A.E. DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 200 U.A.E. IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 201 U.A.E. STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 202 U.A.E. STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 203 U.A.E. STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 204 ISRAEL STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 205 ISRAEL ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 206 ISRAEL HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 207 ISRAEL STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 208 ISRAEL TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 209 ISRAEL MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 210 ISRAEL BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 211 ISRAEL ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 212 ISRAEL THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 213 ISRAEL CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 214 ISRAEL BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 215 ISRAEL ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 216 ISRAEL ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 217 ISRAEL ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 218 ISRAEL TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 219 ISRAEL STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 220 ISRAEL SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 221 ISRAEL MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 222 ISRAEL BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 223 ISRAEL MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 224 ISRAEL ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 225 ISRAEL PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 226 ISRAEL MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 227 ISRAEL MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 228 ISRAEL SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 229 ISRAEL OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 230 ISRAEL DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 231 ISRAEL IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 232 ISRAEL STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 233 ISRAEL STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 234 ISRAEL STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 235 KUWAIT STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 236 KUWAIT ISCHEMIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 237 KUWAIT HEMORRHAGIC STROKE IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 238 KUWAIT STROKE MARKET, BY DIAGNOSIS AND TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 239 KUWAIT TREATMENT IN STROKE MARKET, BY TREATMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 240 KUWAIT MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 241 KUWAIT BLOOD PRESSURE MEDICINE IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 242 KUWAIT ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 243 KUWAIT THIAZIDE DIURETICS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 244 KUWAIT CALCIUM CHANNEL BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 245 KUWAIT BETA BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 246 KUWAIT ALPHA-BLOCKERS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 247 KUWAIT ANTIPLATELET DRUGS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 248 KUWAIT ANTICOAGULANTS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 249 KUWAIT TISSUE PLASMINOGEN ACTIVATOR (TPA) IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 250 KUWAIT STATINS IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 251 KUWAIT SUPPORTIVE MEDICATION IN STROKE MARKET, BY CLASS, 2018-2032 (USD THOUSAND)
TABLE 252 KUWAIT MEDICATION IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 253 KUWAIT BRANDED IN STROKE MARKET, BY DRUG TYPE, 2018-2032 (USD THOUSAND)
TABLE 254 KUWAIT MEDICATION IN STROKE MARKET, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD THOUSAND)
TABLE 255 KUWAIT ORAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 256 KUWAIT PARENTERAL IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 257 KUWAIT MEDICATION IN STROKE MARKET, BY MODE OF PURCHASE, 2018-2032 (USD THOUSAND)
TABLE 258 KUWAIT MEDICATION IN STROKE MARKET, BY THERAPY TYPE, 2018-2032 (USD THOUSAND)
TABLE 259 KUWAIT SURGERY IN STROKE MARKET, BY INSTRUMENT TYPE, 2018-2032 (USD THOUSAND)
TABLE 260 KUWAIT OTHER THERAPY IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 261 KUWAIT DIAGNOSIS IN STROKE MARKET, BY DIAGNOSIS TYPE, 2018-2032 (USD THOUSAND)
TABLE 262 KUWAIT IMAGING TEST IN STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
TABLE 263 KUWAIT STROKE MARKET, BY GENDER, 2018-2032 (USD THOUSAND)
TABLE 264 KUWAIT STROKE MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 265 KUWAIT STROKE MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 266 REST OF MIDDLE EAST AND AFRICA STROKE MARKET, BY TYPE, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA STROKE MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA STROKE MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA STROKE MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA STROKE MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA STROKE MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA STROKE MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 MIDDLE EAST AND AFRICA STROKE MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA STROKE MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCES OF STROKE DRIVE DEMAND FOR TREATMENTS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA STROKE MARKET GROWTH IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 12 ISCHEMIC STROKE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA STROKE MARKET IN THE FORECAST PERIOD OF 2025 & 2032
FIGURE 13 MIDDLE EAST AND AFRICA STROKE MARKET EXECUTIVE SUMMARY
FIGURE 14 STRATEGIC DECISIONS
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA STROKE MARKET
FIGURE 16 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2024
FIGURE 17 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, 2025-2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, CAGR (2025-2032)
FIGURE 19 MIDDLE EAST AND AFRICA STROKE MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2024
FIGURE 21 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, 2025 TO 2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, CAGR (2025- 2032)
FIGURE 23 MIDDLE EAST AND AFRICA STROKE MARKET: BY GENDER, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2024
FIGURE 25 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, CAGR (2025-2032)
FIGURE 27 MIDDLE EAST AND AFRICA STROKE MARKET: BY DIAGNOSIS AND TREATMENT, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2024
FIGURE 29 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
FIGURE 30 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, CAGR (2025-2032)
FIGURE 31 MIDDLE EAST AND AFRICA STROKE MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2024
FIGURE 33 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 34 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, CAGR (2025-2032)
FIGURE 35 MIDDLE EAST AND AFRICA STROKE MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA STROKE MARKET: SNAPSHOT (2024)
FIGURE 37 MIDDLE EAST AND AFRICA STROKE MARKET: COMPANY SHARE 2024 (%)
